NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The medical research company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The company's quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

6 equities research analysts have issued 1 year price objectives for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' share price to reach $25.60 in the next year. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for NeoGenomics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News headlines about NEO stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeoGenomics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,450,000 shares, an increase of 14.4% from the September 30th total of 5,640,000 shares. Based on an average trading volume of 770,800 shares, the days-to-cover ratio is currently 8.4 days. Approximately 6.5% of the shares of the company are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), EXACT Sciences (EXAS), Bio-Rad Laboratories (BIO.B), Elanco Animal Health (ELAN), Henry Schein (HSIC), Bausch Health Companies (BHC), Carl Zeiss Meditec (AFX), Avantor (AVTR), Mylan (MYL), Qiagen (QGEN), Eurofins Scientific (ERFSF), Ono Pharmaceutical (OPHLF), Davita (DVA) and IPSEN S A/S (IPSEY).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), Marvell Technology Group (MRVL), AbbVie (ABBV) and AT&T (T).

NeoGenomics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.59%), Eagle Asset Management Inc. (2.59%), Emerald Mutual Fund Advisers Trust (1.71%), Emerald Advisers LLC (1.67%), Granahan Investment Management Inc. MA (0.94%) and Russell Investments Group Ltd. (0.55%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Castleark Management LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, Gabelli Funds LLC, Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, New York State Teachers Retirement System, Squarepoint Ops LLC, Granahan Investment Management Inc. MA and State of Alaska Department of Revenue. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $26.07.

NeoGenomics has a market capitalization of $2.72 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]